[Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation]

Arnaud Saillant; Ronan Flippot

doi:10.1016/j.bulcan.2020.11.010

[Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation]

Bull Cancer. 2021 Feb;108(2):140-142. doi: 10.1016/j.bulcan.2020.11.010. Epub 2021 Feb 3.

[Article in French]

Authors

Arnaud Saillant¹, Ronan Flippot²

Affiliations

¹ Centre hospitalo-universitaire de Poitiers, département d'oncologie médicale, 86021 Poitiers, France. Electronic address: arnaud.saillant@gmail.com.
² Gustave-Roussy, département de médecine oncologie, Villejuif, France.

PMID: 33546874
DOI: 10.1016/j.bulcan.2020.11.010

No abstract available

Keywords: BRCA; Cancer de prostate métastatique résistant à la castration; Inhibiteurs de Poly(ADP-Ribose) Polymérases; Metastatic castration-resistant prostate cancer; Poly(ADP-ribose) Polymerase Inhibitors.

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
DNA Repair
Drug Approval
France
Genes, BRCA1*
Genes, BRCA2*
Genetic Predisposition to Disease
Humans
Male
Mutation*
Phthalazines / therapeutic use*
Piperazines / therapeutic use*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / genetics

Substances

Antineoplastic Agents
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
olaparib